Form 4: Edgewise Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Alan J Russell, Chief Scientific Officer and a Director of Edgewise Therapeutics, Inc., sold 5,901 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 5,781 Common Stock on August 12, 2026; holds 30,336 after (Direct).
- Option exercise/conversion: acquired 7,031 Common Stock on August 12, 2026; holds 37,367 after (Direct).
- Open-market sale: disposed of 3,238 Common Stock at $43.68 ($141,428) on August 12, 2026; holds 34,129 after (Direct).
- Open-market sale: disposed of 2,273 Common Stock at $43.68 ($99,275) on August 12, 2026; holds 31,856 after (Direct).
- Open-market sale: disposed of 390 Common Stock at $44.46 ($17,339) on August 12, 2026; holds 31,466 after (Direct).
- Option exercise/conversion: disposed of 5,781 Restricted Stock Units on August 12, 2026; holds 11,563 after (Direct).
- Option exercise/conversion: disposed of 7,031 Restricted Stock Units on August 12, 2026; holds 21,094 after (Direct).
- Grant/award: acquired 32,500 Restricted Stock Units on August 12, 2026; holds 32,500 after (Direct).
- Grant/award: acquired 65,000 Stock Option (Right to Buy) on August 12, 2026; holds 65,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $258,042 of stock on the open market.
Insider Transactions
Alan J Russell — Director, Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 5,781 | — | — | 30,336 |
| 2026-08-12 | Option exercise/conversion | Common Stock | 7,031 | — | — | 37,367 |
| 2026-08-12 | Open-market sale | Common Stock | 3,238 | $44 | $141.4K | 34,129 |
| 2026-08-12 | Open-market sale | Common Stock | 2,273 | $44 | $99.3K | 31,856 |
| 2026-08-12 | Open-market sale | Common Stock | 390 | $44 | $17.3K | 31,466 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 5,781 | — | — | 11,563 |
| 2026-08-12 | Option exercise/conversion | Restricted Stock Units | 7,031 | — | — | 21,094 |
| 2026-08-12 | Grant/award | Restricted Stock Units | 32,500 | — | — | 32,500 |
| 2026-08-12 | Grant/award | Stock Option (Right to Buy) | 65,000 | — | — | 65,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (5,781 shares) |
| 2026-08-12 | Option exercise/conversion (7,031 shares) |
| 2026-08-12 | Open-market sale (3,238 shares) |
| 2026-08-12 | Open-market sale (2,273 shares) |
| 2026-08-12 | Open-market sale (390 shares) |
| 2026-08-12 | Option exercise/conversion (5,781 shares) |
| 2026-08-12 | Option exercise/conversion (7,031 shares) |
| 2026-08-12 | Grant/award (32,500 shares) |
| 2026-08-12 | Grant/award (65,000 shares) |
Keywords
insider transaction, Form 4, EWTX, Edgewise Therapeutics, Inc., bearish, Alan J Russell
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.